Global R&D expenditure for pharmaceuticals. Statista https://www.statista.com/statistics/309466/global-r-and-d-expenditure-for-pharmaceuticals/#::̃text=In%202022%2C%20research%20and%20development,principal%20agency%20associated%20with%20processes (2025).
Grand View Research Clinical trials market size, share & trends analysis report by phase (phase I, phase II, phase III, phase IV), by study design, by indication (pain management, oncology, CNS condition, diabetes, obesity), by region, and segment forecasts, 2022–2030. Research and Markets https://www.researchandmarkets.com/reports/4396385/clinical-trials-market-size-share-and-trends (2022).
Scannell, J. W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191–200 (2012).
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M. & Granger, C. B. Fundamentals of Clinical Trials (Springer, 2015).
Sinha, K., Ghosh, N. & Sil, P. C. A review on the recent applications of deep learning in predictive drug toxicological studies. Chem. Res. Toxicol. 36, 1174–1205 (2023).
Lu, Y. et al. Machine learning for synthetic data generation: a review. Preprint at https://arxiv.org/abs/2302.04062 (2023).
Ross, J. S., Mulvey, G. K., Hines, E. M., Nissen, S. E. & Krumholz, H. M. Trial publication after registration in ClinicalTrials.gov: a cross-sectional analysis. PLoS Med. 6, e1000144 (2009).
Zarin, D. A., Tse, T., Williams, R. J., Califf, R. M. & Ide, N. C. The ClinicalTrials.gov results database—update and key issues. N. Engl. J. Med. 364, 852–860 (2011).
Zarin, D. A., Tse, T., Williams, R. J. & Carr, S. Trial reporting in ClinicalTrials.gov—the final rule. N. Engl. J. Med. 375, 1998–2004 (2016).
Johnson, A. E. W. et al. MIMIC-IV, a freely accessible electronic health record dataset. Sci. Data 10, 1 (2023).
Chen, J. et al. Trialbench: multi-modal artificial intelligence-ready clinical trial datasets. Preprint at https://arxiv.org/abs/2407.00631 (2024).
Rajpurkar, P. et al. Evaluation of a machine learning model based on pretreatment symptoms and electroencephalographic features to predict outcomes of antidepressant treatment in adults with depression: a prespecified secondary analysis of a randomized clinical trial. JAMA Netw. Open 3, e206653 (2020).
Hong, Z.-Y., Shim, J., Son, W. C. & Hwang, C. Predicting successes and failures of clinical trials with an ensemble LS-SVR. Preprint at medRxiv https://doi.org/10.1101/2020.02.05.20020636 (2020).
Qi, Y. & Tang, Q. Predicting phase 3 clinical trial results by modeling phase 2 clinical trial subject level data using deep learning. In Proc. 4th Machine Learning for Healthcare Conference (eds Doshi-Velez, F. et al.) 288–303 (PMLR, 2019).
Lo, A. W., Siah, K. W. & Wong, C. H. Machine learning with statistical imputation for predicting drug approvals. Harvard Data Science Review 1, 1 (2019).
Stergiopoulos, S., Getz, K. A. & Blazynski, C. Evaluating the completeness of ClinicalTrials.gov. Ther. Innov. Regul. Sci. 53, 307–317 (2019).
Feijoo, F., Palopoli, M., Bernstein, J., Siddiqui, S. & Albright, T. E. Key indicators of phase transition for clinical trials through machine learning. Drug Discov. Today 25, 414–421 (2020).
Gayvert, K. M., Madhukar, N. S. & Elemento, O. A data-driven approach to predicting successes and failures of clinical trials. Cell Chem. Biol. 23, 1294–1301 (2016).
Artemov, A. V. et al. Integrated deep learned transcriptomic and structure-based predictor of clinical trials outcomes. Preprint at bioRxiv https://doi.org/10.1101/095653 (2016).
Willigers, B. J., Nagarajan, S., Ghiorghui, S., Darken, P. & Lennard, S. Algorithmic benchmark modulation: a novel method to develop success rates for clinical studies. Clin. Trials https://doi.org/10.1177/17407745231207858 (2023).
Fu, T., Huang, K. & Sun, J. Automated prediction of clinical trial outcome. US patent 17/749,065 (2023).
Malik, L. et al. Predicting success in regulatory approval from phase I results. Cancer Chemother. Pharmacol. 74, 1099–1103 (2014).
DiMasi, J. et al. A tool for predicting regulatory approval after phase II testing of new oncology compounds. Clin. Pharmacol. Ther. 98, 506–513 (2015).
Improving public access to aggregate content of ClinicalTrials.gov. CTTI https://aact.ctti-clinicaltrials.org/ (2024).
Fu, T., Huang, K., Xiao, C., Glass, L. M. & Sun, J. HINT: hierarchical interaction network for clinical-trial-outcome predictions. Patterns 3, 100445 (2022).
McHugh, M. L. Interrater reliability: the kappa statistic. Biochem. Med. 22, 276–282 (2012).
Wang, Z., Xiao, C. & Sun, J. SPOT: sequential predictive modeling of clinical trial outcome with meta-learning. In Proc. 14th ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics 1–11 (ACM, 2023).
Lu, Y. et al. Uncertainty quantification and interpretability for clinical trial approval prediction. Health Data Sci. 4, 0126 (2024).
Aliper, A. et al. Prediction of clinical trials outcomes based on target choice and clinical trial design with multi-modal artificial intelligence. Clin. Pharmacol. Ther. 114, 972–980 (2023).
Califf, R. M. et al. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007–2010. JAMA 307, 1838–1847 (2012).
Tasneem, A. et al. The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty. PLoS ONE 7, e33677 (2012).
Anderson, M. L. et al. Compliance with results reporting at ClinicalTrials.gov. N. Engl. J. Med. 372, 1031–1039 (2015).
Huser, V. & Cimino, J. J. Linking ClinicalTrials.gov and PubMed to track results of interventional human clinical trials. PLoS ONE 8, e68409 (2013).
Ratner, A. J., De Sa, C. M., Wu, S., Selsam, D. & Ré, C. Data programming: creating large training sets, quickly. Adv. Neural Inf. Process. Syst. 29, 3567–3575 (2016).